Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Up 320.8% in April
increase of 12.5% from the March 31st total of 182,500 shares. Based on an average daily volume of 213,200 shares, the short-interest ratio is presently 1.0 days. Eloxx Pharmaceuticals saw an increase in short interest in April. As of April 15th, there was short interest totalling 206,200 shares,
() experienced a significant rise in short interest during the month of March. On April 15th there were 206,200 short shares. This is a 320.8% increase from the total of 49,00 shares on March 31st. The days-to-cover is currently 0.9 based on a daily average trading volume of 238,700 share. At the moment, 14.1% are shorted.
Inflows of Institutional Capital and Outflows
Recently, a hedge fund increased its stake in Eloxx Pharmaceuticals. According to the latest disclosure filed with the Securities and Exchange Commission, ) increased by 238.0% during the first quarter. The company now owns 58,213 of the stock, after adding 40,990 more shares in the last quarter. Trading on Friday saw a $0.19 increase, bringing the price to $7.40. The company's shares were traded at a volume of 27,073 compared to the average of 276,245. Eloxx Pharmaceuticals's 1 year low is $1.70, and its 1 year high is $19.20. The stock's 50-day moving average is $4.60, and its 200-day moving average is $2.99. The company has a $16.06 million market cap, a P/E of -0.45 as well as a beta value of 2.69.
The company released its last quarterly earnings report on Monday, 3rd April. The company's ($2.92) earnings-per-share (EPS) for this quarter exceeded the consensus estimate ($2.97) by $0.05. Analysts predict that Eloxx Pharmaceuticals' earnings per share will be -8.26 for the current fiscal.
Wall Street analysts weigh in
Separately Oppenheimer reiterated a 'outperform’ rating and set $50.00 as the price target on Eloxx Pharmaceuticals shares in a research report on Thursday, 6th April.
Eloxx Pharmaceuticals
Get Rating
)
Eloxx Pharmaceuticals, Inc is engaged in the development and manufacture of novel ribonucleic acids-modulating drug candidate. The company focuses on the formulation of medications to treat rare and extremely-rare premature stop code diseases. The company's leading product candidate is ELX02, a small molecule designed to restore full-length functional protein production.
MarketBeat.com offers a FREE daily email newsletter
.